Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks

Clinical Drug Investigation

Volumn 35, Issue 3, 2015, Pages 211-219

  Quercia, Romina ^a   Roberts, Jeremy ^b   Martin Carpenter, Louise ^a   Zala, Carlos ^c  

^a VIIV HEALTHCARE   (United States)

^b GLAXOSMITHKLINE   (Canada)

^c Hospital Central de San Isidro   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DARUNAVIR; FUSED HETEROCYCLIC RINGS; LIPID; RITONAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; HIV INFECTIONS; META ANALYSIS; TIME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CLINICAL TRIALS AS TOPIC; DARUNAVIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; LIPIDS; MALE; RALTEGRAVIR POTASSIUM; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925484336     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0266-2     Document Type: Article

References (23)

1. Cohan GR. HIV-associated metabolic and morphologic abnormality syndrome: welcome therapy may have unwelcome effects. Postgrad Med. 2000;107:141–6.
2. Feeney ER, Mallon PW. HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J. 2011;5:49–63.
3. Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top HIV Med. 2010;18:112–8.
4. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–93.
5. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Extended SPRING-2 study group, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927–35.
6. Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–43.
7. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Extended SAILING study team, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700–8.
8. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, SINGLE investigators, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.
9. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, ING114915 study team, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–31.
10. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV-infected individuals from the HHS panel on antiretroviral guidelines for adults and adolescents. 2013. Available at: http://aidsinfo.nih.gov/contentfiles/upload/adultarv_instirecommendations.pdf. Accessed 1 Nov 2013.
11. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–8.
12. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Adult AIDS Clinical Trial Group Cardiovascular Subcommittee and the HIV Medical Association of the Infectious Disease Society of America, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–27.
13. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
14. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.
15. Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807–16.
16. Kirchner JT. A tolerability review of non-nucleoside reverse transcriptase inhibitors: focus on laboratory measures of clinical relevance. J Antivir Antiretrovir. 2012;4:94–100.
17. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.
18. Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1878–88.
19. Sax P, Tierney C, Collier AC, Daar ES, Mollan K. Abacavir-lamivudine versus tenofovir-emtricitabine. N Engl J Med. 2009;361:2230–40.
20. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Study 934 Group, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60.
21. Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, et al. SWIFT: prospective 48-week study to evaluate safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56:1637–45.
22. Santos JR, Saumoy M, Curran A, Bravo I, Navarro J, Estany C, et al. Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. J Int AIDS Soc. 2014;17:19550.
23. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;11:1120–6.